Efficacy, Safety, and Tolerability of Ambien (Zolpidem) in the Treatment of Children Ages 6 to 17 With Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia (Zolkids)

Inclusion Criteria: Male or female between the ages of 6 and 17 years, inclusive Children with diagnosed ADHD (as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision [DSM-IV-TR] criteria) Complaint of childhood insomnia as defined by repeated difficulty with sleep initiation or consolidation that occurs despite adequate age, appropriate time, and opportunity for sleep The sleep disturbance must not be attributable to either the direct physiologic effect of drug abuse or misuse of a prescribed medication. Subjects should be stabilized on all long-term therapy, including treatment of ADHD, for at least one month prior to study entry. Subjects, if females of childbearing potential (as determined by the initiation of menses), must have confirmed negative pregnancy test prior to randomization and be using a recognized effective method of birth control (oral, implant, depot or transdermal oestroprogestatives, intrauterine device, double-barrier with spermicide). Abstinence is an acceptable method of birth control for this study. Exclusion Criteria: Mental retardation Autistic spectrum disorder A history of sleep apnea A history of bipolar disorder, conduct disorder, major depression, or generalized anxiety disorder (not obsessive compulsive disorder), as determined by clinical interview and DSM-IV-TR criteria Current history of substance abuse/dependence Known hypersensitivity to zolpidem or previous adverse experience with zolpidem Pregnant or breast-feeding Current use of hypnotics, antihistamines, melatonin, herbal products, or other sleep aids